The upcoming days Lifecare will be productive and important for Lifecare in inBerlin where two presentations will be held at the prestigious conference ATTD.The company will also attend the steering committee of the FORGETDIABETESconsortium. PRESENTATIONS AT ATTD IN BERLIN In the next days, Lifecare will participate at the 16th International Conferenceon Advanced Technologies & Treatments for Diabetes (ATTD 2023) in Berlin. Thecompany's CSO, Prof. Dr. Dr. Andreas Pfützner, is invited to give twopresentations at the conference. CSO Prof. Pfützner will give a presentation about the successful miniaturizationof Lifecare's proprietary osmotic-pressure based glucose sensor for continuousintra peritoneal and subcutaneous glucose monitoring by means of nanotechnology.Lifecare's CSO will also explain how this technology has been developed withsuccessful results without compromising sensitivity or functionality. In addition to the presentation about the Sencell, Prof. Dr. Dr. Pfützner willpresent Lifecare's "Dynamic CGM interference testing method" as an E-poster. FORGETDIABETES STEERING COMMITTEE Lifecare is part of the prestigious EU funded research project FORGETDIABETES,where the company in cooperation with German, Italian and French academicinstitutions aim to develop an implantable artificial pancreas. Today, Lifecareis attending the project steering committee for discussions of progress and tocoordinate the upcoming preclinical tests of the prototype artificial pancreas.
Lifecares primary tasks in the project is to develop the sensing element - an"implantable intra peritoneal sensor", as well as an in-vitro test system fordynamic interference testing of glucose sensors, through Lifecares wholly ownedsubsidiary Lifecare Laboratory. In 2020 the European Commission granted theproject funding of 3,9 million EUR under the Horizon 2020 program. Last autumn EU's Innovation Radar analyzed four key inventions in the projectand concluded that two Lifecare-innovations are considered as key-inventions- the implantable intra peritoneal sensor and the in-vitro test system fordynamic interference testing of glucose sensors - is considered as "MARKETREADY". Furthermore, based on signals from the Innovation Radar analyze, Lifecare'sinventions has been categorized in terms of disruptive potential based on thenovel indicator system "Market Creation Potential Indicator" (MCPI) developed bythe European Commission's Joint Research Centre. Lifecares inventions have been categorized with a "HIGH" market potential, thesecond highest category placing both Lifecare inventions among the top 14 % ofall EU-funded innovations.
Further information Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.attme.dev,+47 40 05 90 40
This stock exchange announcement was published by Joacim Holter, CEO at LifecareAS, on 22.2.23 at 08:15 CET.
This is Lifecare: Lifecare is a Bergen-based technology company developing a miniaturizedimplantable long-term sensor for correct and continuous monitoring of bloodsugar in people with diabetes. The Company's patented technology also has thepotential for use in various biomarkers. Lifecare AS is listed on EuronextGrowth (LIFE).